"Anti-Allergic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475)
| Descriptor ID |
D018926
|
| MeSH Number(s) |
D27.505.954.016
|
| Concept/Terms |
Anti-Allergic Agents- Anti-Allergic Agents
- Agents, Anti-Allergic
- Anti Allergic Agents
- Anti-Allergy Drugs
- Anti Allergy Drugs
- Drugs, Anti-Allergy
- Antiallergy Agents
- Agents, Antiallergy
- Antiallergic Drugs
- Drugs, Antiallergic
- Antiallergics
- Anti-Allergics
- Anti Allergics
- Antiallergic Agents
- Agents, Antiallergic
|
Below are MeSH descriptors whose meaning is more general than "Anti-Allergic Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Allergic Agents".
This graph shows the total number of publications written about "Anti-Allergic Agents" by people in this website by year, and whether "Anti-Allergic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 4 | 2 | 6 |
| 2009 | 3 | 1 | 4 |
| 2011 | 1 | 2 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2018 | 1 | 2 | 3 |
| 2019 | 2 | 0 | 2 |
| 2020 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-Allergic Agents" by people in Profiles.
-
Bielory L, Tabliago NRA. Flavonoid and cannabinoid impact on the ocular surface. Curr Opin Allergy Clin Immunol. 2020 10; 20(5):482-492.
-
Kimchi N, Bielory L. The allergic eye: recommendations about pharmacotherapy and recent therapeutic agents. Curr Opin Allergy Clin Immunol. 2020 08; 20(4):414-420.
-
Bielory L, Gross GN, Letierce A, Melas-Melt L, Lucio L. Ocular symptoms improvement from intranasal triamcinolone compared with placebo and intranasal fluticasone propionate: A meta-analysis. Ann Allergy Asthma Immunol. 2020 06; 124(6):616-621.e3.
-
Khan RS, Rizvi S, Syed BA, Bielory L. Current market trends in anterior ocular inflammatory disease landscape. Curr Opin Allergy Clin Immunol. 2019 10; 19(5):503-509.
-
Bielory L, Schoenberg D. Emerging Therapeutics for Ocular Surface Disease. Curr Allergy Asthma Rep. 2019 02 28; 19(3):16.
-
Pandit SA, Glass LRD. Non-glaucoma periocular allergic, atopic, and irritant dermatitis at an academic institution: A retrospective review. Orbit. 2019 Apr; 38(2):112-118.
-
Hadjokas NP, Reidy JJ, Farooq AV. Chronic Follicular Conjunctivitis in a Middle-aged Woman. JAMA Ophthalmol. 2018 07 01; 136(7):833-834.
-
Berger W, Sher E, Gawchik S, Fineman S. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial. Allergy Asthma Proc. 2018 Mar 01; 39(2):110-116.
-
Kruszewski PG, Russo JM, Franciosi JP, Varni JW, Platts-Mills TA, Erwin EA. Prospective, comparative effectiveness trial of cow's milk elimination and swallowed fluticasone for pediatric eosinophilic esophagitis. Dis Esophagus. 2016 May; 29(4):377-84.
-
Nye M, Rudner S, Bielory L. Emerging therapies in allergic conjunctivitis and dry eye syndrome. Expert Opin Pharmacother. 2013 Aug; 14(11):1449-65.